# Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

> **NCT03443960** · PHASE1 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** TNX-102 SL 5.6 mg
- **DRUG:** Amrix 30 mg

## Key facts

- **NCT ID:** NCT03443960
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-29
- **Primary completion:** 2018-04-09
- **Final completion:** 2018-04-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443960, "Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03443960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*